Information needs of post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy

被引:8
|
作者
Feldman-Stewart, Deb [1 ,2 ]
Madarnas, Yolanda [2 ]
Mates, Mihaela [2 ,3 ]
Tong, Christine [1 ]
Grunfeld, Eva [4 ]
Verma, Shailendra [5 ]
Carolan, Hannah [6 ]
Brundage, Michael [1 ,2 ,3 ]
机构
[1] Queens Univ, Canc Res Inst, Div Canc Care & Epidemiol, Kingston, ON K7L 3N6, Canada
[2] Queens Univ, Dept Oncol, Kingston, ON K7L 3N6, Canada
[3] Queens Univ, Canc Ctr Southeastern Ontario, Kingston, ON K7L 3N6, Canada
[4] Univ Toronto, Dept Family & Community Med, Ontario Inst Canc Res, Toronto, ON M5S 1A1, Canada
[5] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[6] BC Canc Agcy, Vancouver, BC, Canada
关键词
Breast cancer; Patient education; Adjuvant endocrine therapy decision; Patient information needs; PROSTATE-CANCER; RADIOTHERAPY; PREFERENCES; CHEMOTHERAPY; SATISFACTION; TRIAL;
D O I
10.1016/j.pec.2013.03.019
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: To identify questions that post-menopausal women with receptor-positive early-stage breast cancer want answered before their adjuvant-endocrine-therapy decision is made. Methods: We surveyed patients eligible for adjuvant-endocrine therapy in the previous 3-18 months. Participants rated the importance of getting each of 95 questions answered before the decision is made (options: essential/desired/not important or no opinion/avoid). For each question rated "essential"/"desired", the participant also identified the purpose(s) for the answer: to help her understand, decide, plan, or other reason(s). Results: The response rate was 55% (188/343). Participants rated a mean of 57 (range: 1-95) questions "essential", 80 (range: 1-95) "essential" or "desired", and 2 (range: 0-27) "avoid". Every question was "essential" to >31% of participants, and "essential"/"desired" to >63%. All but eleven questions were rated as "avoid" by >1 participant. The most frequent purPoses for "essential" questions were to: understand their situations (mean 45, range: 0-95), decide (mean 18, range: 0-94), and plan (mean 13, range: 0-95). Conclusion: Many patients want a lot of information before this decision is made but there is wide variation within the group in both the number and in which questions they want answered. Practice implications: Patient education in this setting needs to be tailored to the needs of the individual patient. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:114 / 121
页数:8
相关论文
共 50 条
  • [1] Information for decision making by post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy
    Feldman-Stewart, Deb
    Madarnas, Yolanda
    Mates, Mihaela
    Tong, Christine
    Grunfeld, Eva
    Verma, Shailendra
    Carolan, Hannah
    Brundage, Michael
    [J]. BREAST, 2013, 22 (05): : 919 - 925
  • [2] Adjuvant Endocrine Therapy for Pre-menopausal Women with Hormone Receptor Positive Early-stage Breast Cancer
    Kendall, S.
    Robinson, T.
    Braybrooke, J.
    Strawson-Smith, T.
    [J]. CLINICAL ONCOLOGY, 2022, 34 (04) : E179 - E179
  • [3] Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer
    Erman, Aysegul
    Nugent, Arlene
    Amir, Eitan
    Coyte, Peter C.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (02) : 267 - 279
  • [4] Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer
    Aysegul Erman
    Arlene Nugent
    Eitan Amir
    Peter C. Coyte
    [J]. Breast Cancer Research and Treatment, 2014, 145 : 267 - 279
  • [5] Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer
    Park, Chanhyun
    Heo, Ji-Haeng
    Mehta, Sanica
    Han, Sola
    Spencer, Jennifer C.
    [J]. CLINICAL DRUG INVESTIGATION, 2023, 43 (03) : 167 - 176
  • [6] Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer
    Chanhyun Park
    Ji-Haeng Heo
    Sanica Mehta
    Sola Han
    Jennifer C. Spencer
    [J]. Clinical Drug Investigation, 2023, 43 : 167 - 176
  • [8] Controversies in adjuvant endocrine therapy for pre- and post-menopausal women with breast cancer
    Ciccarese, Mariangela
    Lorusso, Vito
    De Laurentis, Michele
    [J]. EJC SUPPLEMENTS, 2008, 6 (14): : 4 - 9
  • [9] Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada
    Phillip S. Blanchette
    Melody Lam
    Lucie Richard
    Britney Allen
    Salimah Z. Shariff
    Ted Vandenberg
    Kathleen I. Pritchard
    Kelvin K. W. Chan
    Alexander V. Louie
    Danielle Desautels
    Jacques Raphael
    Craig C. Earle
    [J]. Breast Cancer Research and Treatment, 2020, 179 : 217 - 227
  • [10] Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada
    Blanchette, Phillip S.
    Lam, Melody
    Richard, Lucie
    Allen, Britney
    Shariff, Salimah Z.
    Vandenberg, Ted
    Pritchard, Kathleen I.
    Chan, Kelvin K. W.
    Louie, Alexander V.
    Desautels, Danielle
    Raphael, Jacques
    Earle, Craig C.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (01) : 217 - 227